HHK101
/ Zhuhai Huahaikang Pharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 12, 2026
Phase I Trial of HHK101 in Patients With Schizophrenia
(clinicaltrials.gov)
- P1 | N=125 | Not yet recruiting | Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
New P1 trial • CNS Disorders • Psychiatry • Schizophrenia
1 to 1
Of
1
Go to page
1